Update on topical glucocorticoid use in children

Current Opinion in Pediatrics

Volumn 24, Issue 1, 2012, Pages 121-128

  Morley, Keith W ^a   Dinulos, James G ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

corticosteroids; steroid allergy; steroid phobia; steroid potency; topical glucocorticoids

Indexed keywords

ALCLOMETASONE DIPROPIONATE; AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CLOBETASONE BUTYRATE; DERMASMOOTHE; DESONIDE; DESOXIMETASONE; DEXAMETHASONE; DIFLORASONE DIACETATE; DIFLUCORTOLONE VALERATE; FLUDROCORTISONE ACETATE; FLUDROXYCORTIDE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUOCORTOLONE CAPROATE; FLUORONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; HYDROCORTISONE VALERATE; METHYLPREDNISOLONE; MOMETASONE FUROATE; PREDNICARBATE; PREDNISONE; TOLNAFTATE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CHILD CARE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; HIRSUTISM; HUMAN; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAUTERINE GROWTH RETARDATION; PATIENT COMPLIANCE; PERIORAL DERMATITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PURPURA; REVIEW; ROSACEA; SKIN ABSORPTION; SKIN ATROPHY; TELANGIECTASIA; WOUND HEALING IMPAIRMENT; XEROSIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; FEMALE; GLUCOCORTICOIDS; GUIDELINES AS TOPIC; HUMANS; HYDROCORTISONE; INFANT; MALE; PATIENT COMPLIANCE; RECEPTORS, GLUCOCORTICOID;

EID: 84856100388     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834ef53d     Document Type: Review

References (20)

1. Whitehouse W. Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacol 2011; 19:1-19. This article presents a broad overview of the history of topical glucocorticoids and raises important questions concerning their safety.
2. Fraser R, Gower D, Honour J, et al. Analysis of corticosteroids. In Makin H and Gower D, editors. Steroid analysis. 2nd ed. New York: Springer; 2010. pp. 329-455.
3. Rose A, Vegiopoulos A, Herzig S. Role of glucocorticoids and the glucorticoid receptor in metabolism: insights from genetic mutation. J Steroid Biochem Mol Biol 2010; 122:10-20.
4. Barnes P. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010; 120:76-85.
5. Barnes P. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163:29-43.
6. Strohmayer E, Krakoff L. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011; 40:409-417.
7. Donatti T, Koch V, Takayama L, et al. Effects of glucocorticoids on growth and bone mineralization. J Pediatr (Rio J) 2011; 87:4-12.
8. Pileggi F, Martinelli C, Tazima M, et al. Is suppression of hypothalamicpituitary- adrenal axis significant during clinical treatment of phimos? J Urol 2010; 183:2327-2331.
9. Hepburn D, Yohn J, Weston W. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994; 9:225-254. While this study is now over 15 years old, it still contains one of the clearest reviews of the factors affecting steroid potency, particularly in the pediatric population.
10. Bhat Y, Manzoor S, Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol 2011; 56:30-32.
11. Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 2011; 25:508-515.
12. Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review of literature. Endocrine 2010; 38:328-334.
13. Nieman L. Consequences of systemic absorption of topical glucocorticoids. J Am Acad Dermatol 2011; 65:250-252.
14. Horn E, Domm S, Katz H, et al. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol 2010; 24:119-124. This review expands upon the therapeutic options available to optimize the therapeutic index of topical corticosteroids.
15. Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. 2011; 28: 293-296. This concise article discusses the disparity between the perceived risk of skin atrophy and observed clinical data.
16. Chi C, Mayon-White R, Wojnarowska F. Safety of topical corticosteroids in pregnancy: a population-based cohort study. J Invest Dermatol 2011; 131:884-891.
17. Browne F, Wilkinson S. Effective prescribing in steroid allergy: controversies and cross-reactions. Clin Dermatol 2011; 29:287-294.
18. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011. [Epub ahead of print] The complex phenomenon of steroid phobia is explored in this interesting study.
19. Yentzer B, Camacho F, Young T, et al. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. J Drugs Dermatol 2010; 9:324-329.
20. Yentzer B, Ade R, Fountain J, et al. Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. Cutis 2010; 86:208-213.